ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET
Company Participants
Judy DiClemente – IR
Nikhil Lalwani – President and CEO
Steve Carey – CFO
Christopher Mutz – Head, Rare Disease
Conference Call Participants
Elliot Wilbur – Raymond James
Brandon Folkes – Cantor Fitzgerald
Greg Fraser – Truist Securities
Operator
Good morning, everyone. My name is Todd, and I’ll be your conference operator. At this time, I’d like to welcome everyone to ANI Pharmaceuticals Third Quarter 2022 Financial Results. [Operator Instructions] As a reminder, this conference call is being recorded today, November 9, 2022.
It is now my pleasure to turn the floor over to Ms. Judy DiClemente, Investor Relations for ANI Pharmaceuticals. Please go ahead.
Judy DiClemente
Thank you, Todd. Welcome to ANI Pharmaceuticals third quarter 2022 earnings results call. This is Judy DiClemente of Insight Communications, Investor Relations for ANI. With me on today’s call are Nikhil Lalwani, President and Chief Executive Officer; Steven Carey, Chief Financial Officer; and Christopher Mutz, Head of Rare Disease of ANI. You can also access the webcast of this call through the Investors section of the ANI website at anipharmaceuticals.com.
Before we get started, I’d like to remind everyone that any statements made on today’s conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company’s future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to ANI Pharmaceuticals management as of today and involve risks and uncertainties, including those noted in our press release issued this morning and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. ANI specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. The archived webcast will be available for 30 days on our website, anipharmaceuticals.com.
For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on November 9, 2022. Since then, ANI may have made announcements related to the topics discussed, so please reference the company’s most recent press releases and SEC filings.
And with that, I’ll turn the call over to Nikhil Lalwani. Nikhil?
Nikhil Lalwani
Thank you, Judy. Good morning, everyone and thank you for joining our call.
Our financial results for the third quarter reflect the clarity of our company’s purpose to serve patients in need, alignment of our growth strategy and the dedicated focus on operational execution. I am pleased to share that ANI delivered record net revenues of $83.8 million in the third quarter of 2022 achieving 61% year-over-year growth and 13% quarter-on-quarter growth.
Our non-GAAP EBITDA this year has increased from $4.3 million in Q1 to $9.9 million in Q2 to $19.6 million in the third quarter of 2022. Over the past 12 months, we have further strengthened the foundation of ANI with new capabilities and strategic initiatives to deliver sustainable growth.
First, we have fully operational our integrated rare disease platform with medical affairs, market access, sales and marketing, patient support, specialty distribution and compliance infrastructure and capabilities.
Second, it proven generics in 505(b)(2) R&D engine, further enabled with additional R&D investments towards niche limited competition pipeline products. And third, our ability to drive cost competitiveness by consolidating our manufacturing network to the closure of the facility in Oakville, Canada, and consolidating distribution operations post-acquisition with a third party warehousing and logistics provider.
At this time, we are maintaining our guidance of 2022 total company revenues at $295 million to $315 million and adjusted total company non-GAAP EBITDA guidance at $54 million to $60 million.
Now, let me share details of the progress made across our key business lines. For our rare disease business unit, building a successful Cortrophin Gel franchise remains our top priority. The company achieved strong Cortrophin revenue growth, delivering 12.6 million in sales, up from 10.2 million in the second quarter.
For those new to the ANA story, ANI launched Cortrophin earlier this year in January. Cortrophin is ANDA product than ANI acquired from Merck. In terms of the launch trajectory, I’m pleased to report that cumulative new patient cases initiated increased by greater than 50% to 765 plus cases. We also continue to make further investments in our hub, patient support services and distribution network.
Physician interest in Cortrophin continues to build. The prescriber brace, increased by greater than 50% since our last report to 380 unique prescribers and importantly, approximately one-third of the prescribers have written more than one prescription. Prescriptions continue to be distributed across our targeted indications, which include certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis and access urinary protein due to nephrotic syndrome.
We remain focused on market access and bringing savings to the healthcare system. Our efforts are paying off as patients across commercial Medicare and Medicaid payers have access to our Cortrophin.
We believe that with the addition of Cortrophin into the ACTH market, all stakeholders namely patients, prescribers, payers and pharmacy benefit managers gain another treatment option. Most importantly, we continue to see evidence that our efforts are having a favorable impact on the overall number of patients receiving critical ACTH therapy.
Turning now to the other business segments, Our 3Q generics business revenues grew by 51% over the prior year quarter on the strength of our acquisition execution and success in bringing limited competition drugs to market. We continue to invest in our generics and 505(b)(2) R&D platforms to drive future growth.
During the first nine months of 2022, we filed 11 ANDAs. In the third quarter, we also successfully launched multiple limited competition products including Prochlorperazine Maleate Tablets and Acebutolol Hydrochloride Capsules.
Our previously announced plan to consolidate manufacturing operations and cease operations at the Oakville, Ontario, Canada manufacturing facility in the first quarter of 2023 is on schedule. We have begun manufacturing many of the Oakville products in our U.S. facilities and are starting to see the benefits of the operational efficiencies from this initiative.
As we complete this transition, we remain confident that our Baudette and New Jersey manufacturing sites can support our future growth and provide continuous service to customers and patients in need.
As part of this process, we are actively engaged and have made meaningful progress with a shortlist of potential buyers for Oakville. Once fully executed, this operational efficiency is expected to improve our profitability and cash flow by $7 million to $8 million on an annualized basis. Steve will have more to share on this shortly but we currently expect one-time cash charges of approximately $2.7 million and non-cash charges of $4.4 million in conjunction with this action.
Business development is one of ANIs core strengths, and we continue to actively support our internal efforts when opportunities arise. As previously announced, we completed the acquisition of four limited competition ANDAs from Oakrum Pharma. We expect to see the full impact of these product acquisitions in 2023.
In the established brands business unit, we continue to focus on efficiently promoting our key brands. We utilized a suite of commercialization techniques, including tele sales teams, and ongoing patient support through co-pay assistance and patient starter samples.
For our dermatology portfolio, we have partnered with an established dermatology company and expect our key DERM brands to return to grow on the back of these efforts. We are also actively evaluating business development deals to expand our portfolio of established brands.
Before I turn the call over to Steve, let me share an important recent addition to the ANI leadership team. I’d like to welcome Krista Davis, who joined ANI as Chief Human Resources Officer. Krista brings over 20-years of executive leadership experience in human resources, talent management and organizational development and will no doubt be an asset to the company as we grow and evolve into a leading biopharmaceutical company serving patients in need.
Steve will now walk through our detailed third quarter financial results. Steve?
Steve Carey
Thank you, Nikhil. And good morning to everyone on the call.
My comments this morning will be focused on the three months ended September 30, 2022 versus prior year unless otherwise noted. For the three months ended September 30, 2022, we posted total net revenues of $83.8 million up $31.8 million or 61% as compared to the prior year period, driven by strong gains in both of our operating segments.
Revenues for our generics established brands and other segments were up $19.2 million or 37% over the prior year, while our rare disease segment posted $12.6 million during the current year quarter. Dollarized revenue gains were driven by generic products and the 2022 launch of purified Cortrophin Gel.
Net revenues for generic pharmaceutical products were $53.1 million during the third quarter of 2022 an increase of 51% compared to $35.1 million for the prior year period. The increase was principally driven by revenues from commercial generic products acquired in our acquisition of Novitium and revenues from multiple new product launches partially tempered by a decrease in revenues from sales of several legacy ANI generic products.
Net revenues of rare disease pharmaceutical products, which consist entirely of sales of purified Cortrophin Gel were $12.6 million during the three months ended September 30, 2022. There were no sales of rare disease pharmaceutical products during the comparable prior year period. Royalty and other revenues were $3.5 million in the current year quarter, an increase of $3.3 million from the prior year principally driven by licensing and royalty income related to Novitium products.
Contract manufacturing revenues were $4.8 million during the third quarter of 2022, more than double the $2.4 million posted in the prior year period, primarily related to the addition of Novitium contract manufacturing revenues. Tempering the gains in the above categories were net revenues for established brand pharmaceutical products which were $9.8 million during the three months ended September 30, 2022.
This represents a decrease of 31% compared to $14.3 million for the same period in 2021, driven by lower volumes of many of our brand products, including Arimidex, Inderal LA and Inderal XL. Operating expenses increased by approximately 60% to $88.8 million for the three months ended September 30, 2022 from $55.6 million in the prior year period.
Cost of sales excluding depreciation and amortization increased by $8.5 million to $32.9 million in the third quarter of 2021 compared to $24.4 million in the prior year period primarily due to increased sales volumes of generic products, including $6.5 million of costs related to Novitium products during the current year period with no comparable sales activity in the prior year and an increase of $1.7 million related to increased sales of product subjects to profit sharing arrangements.
Excluding the impact of acquisition accounting, stock-compensation and the effects of our Oakville, Ontario plant closure, all of which are detailed in the tables contained in this morning’s press release. Cost of sales on a non-GAAP basis as a percentage of total adjusted net revenues decreased 4.4 points from 42.6% in the third quarter of 2021 to 38.2% in the current year period.
Primarily as a result of favorable mix from the impact of our sales of purified Cortrophin Gel coupled with increased royalty and other revenues in the current year period. The decrease in cost of sales percentage was partially offset by lower sales of established brand products in the period.
Research and development expenses were $7.7 million in the third quarter of 2022 an increase of $5.2 million from the prior year period, primarily due to expenses related to Novitium generic research and development activities during the current year with no comparable expenses in the prior year, coupled with in process research and development charges of $1.2 million recognized in the current year period in conjunction with purchase accounting for our ANDA acquisition from Oakrum Pharma, LLC.
Selling, general and administrative expenses increased by 75% to $30.1 million in the third quarter of 2022compared to $17.2 million in the prior year quarter primarily due to a $10.3 million increase in sales and marketing expense related to our launch of purified Cortrophin Gel. Increased generic expenses primarily related to the addition of Novitium headcount and activities and tempered by a $0.4 million decrease in transaction expenses related to the Novitium acquisition.
Depreciation and amortization expense was $14.2 million for the three months ended September 30, 2022, compared to $11.3 million for the same period in 2021, an increase of $2.8 million primarily due to the amortization of intangible assets acquired in the Novitium acquisition. We recognized $1.5 million of restructuring expense in the third quarter of 2022 associated with the anticipated closure of our Oakville, Ontario Canada facility.
Costs included $0.4 million in termination benefits and $1.2 million in fixed asset impairment charges and accelerated depreciation. No restructuring activities were recognized in the prior year period. We currently anticipate that we will incur another $0.6 million of severance related cash charges and another $1.9 million to $2.4 million of non-cash accelerated depreciation over the course of the next two quarters.
We have excluded both the one-time charges resulting from this action as well as the residual Canada results from our non-GAAP financial measures as detailed on this morning’s tables in this morning’s press releases.
During the quarter ended September 30, 2022, we also recognized a non-cash fair value adjustment of $2.5 million related to the contingent consideration recorded in conjunction with Novitium purchase accounting. This expense is due to a reduction in the discount rate utilized and the passage of time.
Our $0.55 GAAP net loss per share for the quarter reflect significant amortization and purchase accounting related charges resulting from the Novitium acquisition coupled with the sales and marketing expense behind our initial commercial launch of Cortrophin as well as Oakville related restructuring activities.
On an adjusted non-GAAP basis, we had diluted earnings per share of $0.64 for the quarter compared to $1.01 per share for the prior year period. Adjusted non-GAAP EBITDA for the current year quarter of $19.6 million was up $3 million or nearly 20% as compared to $16.6 million for the third quarter of 2021. An importantly, on a sequential basis, was up $9.7 million or nearly double as compared to the second quarter of this year.
From a cash and balance sheet perspective, the third quarter marked a return to positive cash flow from operations with $3.6 million of cash provided by operations after significant utilization of cash from operations during the first six months of the year as we invested behind the Cortrophin launch.
During the quarter, we also utilized over $7 million of cash in our acquisition of four ANDAs from Oakrum Pharma. As of September 30, balance sheet date, the company had $56.3 million in non-restricted cash and cash equivalents and $297.8 million in face value of outstanding debt, which is due in November of 2027.
Finally, with this morning’s release, we are reiterating the following core elements of our full year 2022 guidance. Total company net revenue between $295 million and $315 million representing approximately 36% to 46% percent growth as compared to $216.1 million recognized in 2021.
Cortrophin specific net revenue guidance between $40 million and $45 million, total company adjusted non-GAAP EBITDA between $54 million and 60 million and adjusted non-GAAP diluted earnings per share between $1.34 and $1.62.
We will now open up the call for questions. Operator, please go ahead with the instructions.
Question-and-Answer Session
Operator
Thank you. [Operator Instructions] We’ll take our first question from Elliot Wilbur of Raymond James.
Elliot Wilbur
Thanks. Good morning. First question with respect to Cortrophin trends in the quarter Nikhil, thinking about the 50% increase in patient cases, initiated 50% plus increase in number of prescribers. Can you just sort of help us bridge those figures versus the actual sequential revenue change in the quarter which is, you know, roughly half that more around 25%. Understanding, obviously, you know, all patients weren’t available for the entire period, but just trying to understand maybe what else may be occurring under the surface there.
And additionally, I want to ask a question on the number of prescribers that have written more than one prescription. You indicated last quarter, it was roughly a third or more than a third. I mean, this quarter, it’s still more than a third. But help us think about sort of persistence of therapy for patients who start if we’re not seeing more meaningful improvement in terms of numbers, prescribers, writing multiple Rx’s. And I’ve got a couple of follow ups for Steve, but I’ll stop there for the moment.
Nikhil Lalwani
And thank you, Elliot, and good morning. So the answer to your first question, look we’re pleased with the launch trajectory, increased physician interest in our product and expanded market access. And, you know, enrollment to fulfilment for Purified Cortrophin Gel is similar to other rare disease products, right? We continue to work closely with the PBMs and payers and invest in our hub and patient support infrastructure. As a result, we continue to see improvement in the new cases converting to patients on therapy. And then obviously, there’s the details of that dynamic. That is, you know, that is responsible for the, I guess, the question that you asked, right 50% increase in number of prescribers, 50% Increase the number of cases initiated, and that matching up with the launch numbers. So that’s the answer to your first question.
And then the second question regarding 380 prescribers and persistence of therapies for existing patients. You know, why don’t I let Chris, take that question?
Christopher Mutz
Yes, thanks. Thanks, Nikhil. You know, as you said, I think we’re very encouraged by the increases we’re seeing and new prescribers as well as repeat prescribers. I think the other piece is that we’re still, we still have a lot of first physicians who are submitting their first prescription for Cortrophin. And so those that have started earlier in the cycle, maybe in 2Q and earlier in 3Q have the ability to then look for more patients to prescribe.
So, on an absolute basis, the number of repeat prescribers is increasing. So we’re very encouraged by that for sure. But we’ll continue to monitor that. We expect that to continue to increase, we make headway into more and more prescribers and more — and based on the positive reception we’re getting.
I think from the standpoint of the patient mix and the persistence, we’re really keeping a close eye on that, because we’re really focused on three different target indications, and they have different — I think, persistent treatment persistence curves, and we’re continuing to look at that. But they are different based on the specialty and [ANDA].
Elliot Wilbur
Okay, thanks. And then just quickly for Steve, has there been any change in the original targeted investment spend, SG&A spend behind the Cortrophin. Asset this year, which I think was originally indicated, be in the range of 42 million to 46 million, are you trending towards the higher end of that range, lower end or have you actually sort of changed that — that metric. And then if you could just comment on gross margin trends, perhaps in the base generics business, revenue was better than ex — or outperform the external expectations, but also look like he had a decent improvement in the margin profile of that portfolio as well, and just trying to tease out those numbers, but just want to get some more color there. Thanks.
Steve Carey
Yes. Thanks, Elliot. And good morning. Both very good questions. In terms of the Cortrophin Gel SG&A numbers, as you’ve probably noted, this morning, we reiterated the core revenue and profitability measures of our annual guidance. We did not specifically update the Cortrophin spend guidance, and that was intentional. You know, as we progress through the fourth quarter and make plans for 2023, we continue to focus on investing in key initiatives to drive future growth, right and set the franchise up for success in 2023.
And so as such, we’re maintaining a degree of flexibility in those spend areas. Broadly speaking, we will be — within our, — close to the ranges that were previously put out, but again, we’re maintaining flexibility to make strategic decisions as we invest into the business as the calendar turns to ’23. As we’re focused, as you would imagine, very focused on the mid and long-term success of the franchise.
On the second question, regarding the gross margins, I’ll speak on it to the overall because we did have a very strong gross margin profile in the third quarter. And within that, I’ll touch on the generics a bit as well.
If you look sequentially right, our non-GAAP adjusted gross margin was 61.1% in the third quarter which is up just a touch over seven points as compared to the second quarter of ’22 and that improvement was driven by multiple factors.
First, favorable mix contributions from purified Cortrophin Gel and the established brands business on a sequential basis, favorable quarter-over-quarter royalty and license income thirdly, incremental revenues from off contract sales of select generic products due to market disruptions and that hones in on your point on the generic profile.
And then lastly, certain operational efficiencies that we’ve begun to realize due to the planned closure of our Oakville, Ontario manufacturing plants as we move products that were manufactured in Oakville into our other manufacturing facilities – we’re gaining efficiencies in those go forward facilities so, really kind of good news in the quarter across multiple platforms, Elliot.
Elliot Wilbur
Okay, thank you.
Operator
Thank you. [Operator Instructions] We’ll take our next question from Brandon Folkes of Cantor Fitzgerald.
Brandon Folkes
Hi, thanks for taking – my questions and congratulations on the progress. Maybe just two from me on Cortrophin, and can you maybe focus market for Cortrophin? Are you seeing it grow year-on-year just [indiscernible] report and decent numbers and you’re putting up decent numbers here? Yes, it does seem that there may be actually the – an underlying growth in the market, but I’d love to get the commentary what you’re seeing there?
And then just following on from the earlier question, can you just provide any color and maybe the number of vial per you’re seeing in the sort of see 150 odd patients start so far or just remind us traditionally what your three target indications what they have averaged? Thank you.
Nikhil Lalwani
Got it, yes thank you Brandon, and good morning. I’ll let Chris answer the first question on overall market growth. And then I’ll take the second one on a number of vials so Chris?
Chris Mutz
Yes, thanks, Nikhil. Yes, so this is something we’ve been closely watching as we all know that there’s been a significant decline in the overall market for the past number of years. And so, we’ve certainly seen the market stabilize and we have seen initial signs of growth. And we feel that is a very positive outcome of our launch and certainly a result of our – in part a result of our educational programming with physicians and the interactions we’re having.
Nikhil Lalwani
Right, and just to build on what Chris just said, as you may have heard in the competitor’s earnings call yesterday that they too have spoken about demand stabilization and it plays out in some of the data that’s available in terms of PRXs. So most importantly, we’re – from what we can see there are more patients beginning to benefit from ACTH therapy than the declining trend that we’ve been seeing in the past few years. And that is – aligned with what we had expected to happen.
And to your second question on number of vials per patient look, our targeted indications continue to include certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis, rheumatoid arthritis, and excess urinary protein due to nephritic syndrome. So directionally the – what we see prescribers use from multiple sclerosis during an acute exacerbation yes is lower than what we see in rheumatoid arthritis and nephritic syndrome.
And obviously, that depends on the patient and the prescriber deciding how many vials to use per patient. But directionally for multiple sclerosis, you see lesser number of vials versus rheumatoid arthritis and nephritic syndrome. And then in terms of further specificity look throughout the initial launch period, we’ve sought to find balance between sharing information to assist the investment community while not giving away competitively sensitive data. So appreciate your understanding on that Brandon and thank you for your questions.
Brandon Folkes
Understand. And thanks so much, and congratulations on the quarter.
Nikhil Lalwani
Thank you.
Operator
Thank you. We’ll take our next question from Greg Fraser with Truist Securities.
Greg Fraser
Good morning, folks. Thanks for taking the question. For Cortrophin in the third quarter, can you talk maybe high level about how much of the growth was driven by new patients versus switches from ACTH? You noticed that the prescriptions have been distributed across your targeted specialties. When do you plan to expand your promotional focus to other specialties that are big writers of ACTH or like pulmonology and ophthalmology.
Nikhil Lalwani
Got it. Good morning, and thank you, Greg, for your questions. Chris, you want to take the first one on new patients versus switches and then I’ll take the second one on expanding focus.
Christopher Mutz
Yes, sure. So, in general, and we’ve talked about this before, our focus really isn’t on the switch market necessarily. I mean, we’re really educating around new patients starts. And so, you know, we think about our market in terms of new patients, and then refills, within a quarter. And so what we can say is that kind of month-over-month, quarter-over-quarter, the proportion of the refill contribution continues to grow. And this is exactly as we expected, and modelled.
So, we’re — as we continue to have new patients. We benefit from the contribution of those new patients in each quarter, and we’re showing steady progress there. But the benefit of the refills also is an important contributor.
Nikhil Lalwani
Yes, and to build on what Chris said, so our discussion with the prescribers is around finding the appropriate patients for our therapy, and not around switching from one therapy to another. So that’s the first question.
And then second, look, I’m sorry for the general response. But throughout the launch period, we’re trying to find balance, Greg as you will appreciate between sharing information to assess the investment community, while not giving competitively sensitive data. We are excited about the opportunities that lie ahead, both in the near term and in the midterm for Purified Cortrophin Gel, and there are multiple such opportunities. But we’ll share more as we progress forward and thank you for your understanding.
Greg Fraser
I totally understand. Thanks for that. One more question on the generic business. Can you comment on base erosion and completion for new launches in the quarter? And for the full year, I guess, are you trending towards your prior expectation for base erosion in the higher single digit to low double digit range? Or are you tracking ahead of that? Thank you.
Nikhil Lalwani
Yes, so I think the question base erosion versus new product launches, I think, as you’ll see in our quarter-on-quarter, much as we plan, the erosion that we’re seeing is made up for by the multiple limited competition, new product launches that we’ve done, so that, you know, that strategy or approach of ours to ensure that we’re launching enough products to make up for the base erosion, you’re seeing the growth quarter-on-quarter in our genetics business, and we expect that to continue.
Then in terms, are we tracking overall below, you know, what we expected, I think that we’re basically in line with the erosion that we had expected.
Greg Fraser
Thank you.
Nikhil Lalwani
Yes, thank you, Greg.
Operator
Thank you. It appears that we have no further questions at this time. I will now turn the floor back over to Nikhil Lalwani for any additional or closing remarks.
Nikhil Lalwani
Thank you. Thank you, everyone for joining our call this morning. We are pleased with the progress made and remain focused on capturing the full potential of our lead rare disease product Cortrophin Gel, all while advancing our active generics and 505(b)(2) R&D engine, to continue delivering high quality medicines to those in need.
As always, we appreciate the support of our shareholders and look forward to sharing our future progress. Thank you again for joining our call and stay well.
Operator
This does conclude today’s call. We thank you for your participation. You may disconnect at any time.
Be the first to comment